Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29461620 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1CHRM3PREPUSP2 | |
| SCHEMBL25064842 | 0.84 | CHRM2 (0.43) | CHRM2CHRM1CHRM3PREPUSP2 | |
| SCHEMBL25064840 | 0.84 | CHRM2 (0.43) | CHRM2CHRM1CHRM3PREPUSP2 | |
| SCHEMBL25092516 | 0.83 | CHRM2 (0.52) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL30260791 | 0.83 | CHRM2 (0.52) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL28681009 | 0.83 | CHRM2 (0.52) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL28649758 | 0.83 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPUSP2 | |
| SCHEMBL30870976 | 0.82 | CHRM2 (0.41) | CHRM2CHRM1CHRM3PREPUSP2 | |
| SCHEMBL22323929 | 0.81 | — | — | |
| SCHEMBL10299786 | 0.81 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | CHRM2 4724/4885CHRM1 4689/4885CHRM3 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.